• Inhibikase Therapeutics sold 25,000,000 common shares to RA Capital Management via its at-the-market facility for gross proceeds of USD 50 million.
• Proceeds, combined with existing cash, expected to fund operations through the Part B topline readout of the Phase 3 IMPROVE-PAH study.
• Runway assumption depends on full exercise of the outstanding Series A and B warrants.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibikase Therapeutics Inc. published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.